Home
/
Anika Therapeutics, Inc.
/
Financials
/
Quarterly
Anika Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Anika Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$27.82M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$28.22M
Jul 30, 2025
Q1
2025
Mar 31, 2025
$26.17M
May 9, 2025
Q3
2025
Sep 30, 2024
$29.56M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$30.72M
Jul 30, 2025
Q1
2025
Mar 31, 2024
$29.02M
May 9, 2025
Q3
2024
Sep 30, 2023
$41.47M
Nov 4, 2024
Q2
2024
Jun 30, 2023
$44.30M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$37.92M
May 8, 2024
Q3
2023
Sep 30, 2022
$40.26M
Nov 3, 2023
Q2
2023
Jun 30, 2022
$39.66M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$36.69M
May 9, 2023
Q3
2022
Sep 30, 2021
$39.54M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$38.15M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$34.29M
May 6, 2022
Q3
2021
Sep 30, 2020
$31.69M
Nov 5, 2021
Q2
2021
Jun 30, 2020
$30.68M
Aug 6, 2021
Q1
2021
Mar 31, 2020
$35.40M
May 7, 2021
Q3
2020
Sep 30, 2019
$29.70M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$30.42M
Aug 7, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2017
$27.18M
Oct 27, 2017
Q2
2017
Jun 30, 2017
$33.46M
Jul 28, 2017
Q1
2017
Mar 31, 2017
$23.39M
May 4, 2017
Q3
2017
Sep 30, 2016
$25.79M
Oct 27, 2017
Q2
2017
Jun 30, 2016
$26.58M
Jul 28, 2017
Q1
2017
Mar 31, 2016
$22.28M
May 4, 2017
Q3
2016
Sep 30, 2015
$23.68M
Nov 1, 2016
Q2
2016
Jun 30, 2015
$22.90M
Aug 1, 2016
Q1
2016
Mar 31, 2015
$15.52M
May 3, 2016
Q3
2015
Sep 30, 2014
$22.06M
Nov 3, 2015
Q2
2015
Jun 30, 2014
$26.27M
Aug 4, 2015
Q1
2015
Mar 31, 2014
$34.01M
May 4, 2015
Q3
2014
Sep 30, 2013
$17.75M
Nov 6, 2014
Q2
2014
Jun 30, 2013
$20.83M
Aug 4, 2014
Q1
2014
Mar 31, 2013
$15.25M
May 5, 2014
Q3
2013
Sep 30, 2012
$14.77M
Nov 5, 2013
Q2
2013
Jun 30, 2012
$19.62M
Aug 6, 2013
Q1
2013
Mar 31, 2012
$14.36M
May 6, 2013
Q3
2012
Sep 30, 2011
$18.46M
Nov 8, 2012
Q2
2012
Jun 30, 2011
$16.14M
Aug 7, 2012
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($2.33M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($3.97M)
Jul 30, 2025
Q3
2025
Jun 30, 2025
($3.97M)
Nov 5, 2025
Q3
2025
Mar 31, 2025
($4.87M)
Nov 5, 2025
Q2
2025
Mar 31, 2025
($4.87M)
Jul 30, 2025
Q1
2025
Mar 31, 2025
($4.87M)
May 9, 2025
Q3
2025
Sep 30, 2024
($29.92M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($88.0K)
Jul 30, 2025
Q3
2025
Jun 30, 2024
($88.0K)
Nov 5, 2025
Q3
2025
Mar 31, 2024
($4.51M)
Nov 5, 2025
Q2
2025
Mar 31, 2024
($4.51M)
Jul 30, 2025
Q1
2025
Mar 31, 2024
($4.51M)
May 9, 2025
Q3
2024
Sep 30, 2023
($6.58M)
Nov 4, 2024
Q3
2024
Jun 30, 2023
($2.74M)
Nov 4, 2024
Q2
2024
Jun 30, 2023
($2.74M)
Aug 8, 2024
Q2
2024
Mar 31, 2023
($10.35M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($10.35M)
May 8, 2024
Q3
2024
Mar 31, 2023
($10.35M)
Nov 4, 2024
Q3
2023
Sep 30, 2022
($4.18M)
Nov 3, 2023
Q2
2023
Jun 30, 2022
($2.84M)
Aug 8, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($3.23M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($4.18M)
Jul 30, 2025
Q1
2025
Mar 31, 2025
($4.28M)
May 9, 2025
Q3
2025
Sep 30, 2024
($81.0K)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($1.81M)
Jul 30, 2025
Q1
2025
Mar 31, 2024
($2.51M)
May 9, 2025
Q3
2024
Sep 30, 2023
($7.67M)
Nov 4, 2024
Q2
2024
Jun 30, 2023
($3.63M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($12.55M)
May 8, 2024
Q3
2023
Sep 30, 2022
($5.80M)
Nov 3, 2023
Q2
2023
Jun 30, 2022
($3.38M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($3.55M)
May 9, 2023
Q3
2022
Sep 30, 2021
$1.30M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$9.18M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$1.26M
May 6, 2022
Q3
2021
Sep 30, 2020
($7.93M)
Nov 5, 2021
Q2
2021
Jun 30, 2020
($9.54M)
Aug 6, 2021
Q1
2021
Mar 31, 2020
$7.09M
May 7, 2021
Q3
2020
Sep 30, 2019
$12.05M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$11.92M
Aug 7, 2020